Tier 2 — strong

The effect of quercetin and citrulline on cycling time trial performance

Jennifer A Kurtz, Jacob Grazer, Kathryn Wilson, Rafaela G Feresin, J Andrew Doyle, Ryan Middleton, Emma Devis, Trisha A VanDusseldorp, Kimberly Fasczewski, Jeff Otis
Journal of the International Society of Sports Nutrition 2024 21(1):2416909

Bibliography

PubMed
PMID 39417670
PubMed Central
PMC11488173
DOI
10.1080/15502783.2024.2416909
Funding
Reported funding/support: Food and Nutrition Service10.13039/100009165 The work was supported by the Food and Nutrition Service. We thank Trisha VanDusseldorp for funding the purchase of supplements for this study.
Competing interests
Reported disclosure: No potential conflict of interest was reported by the author(s).

Study snapshot

DesignRandomized controlled four-arm supplementation trial
ModelHuman intervention research
Sample48 highly trained cyclists in performance analysis
InterventionQuercetin 500 mg twice daily, citrulline, their combination or placebo
Duration28 days
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2024, this source examined exercise and recovery. Design: Randomized controlled four-arm supplementation trial. Sample/model: 48 highly trained cyclists in performance analysis. The exposure or intervention was Quercetin 500 mg twice daily, citrulline, their combination or placebo. Follow-up or treatment period: 28 days.

The combined regimen did not improve 20-km time-trial performance or the main performance measures.

The abstract contains an inconsistent citrulline unit. Related biomarker reports may analyze the same parent cohort; do not count them as separate trials.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Exercise: Performance, Recovery and Muscle. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The combined regimen did not improve 20-km time-trial performance or the main performance measures.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Quercetin 500 mg twice daily, citrulline, their combination or placebo; 28 days.

What this study can and cannot tell us

  • The abstract contains an inconsistent citrulline unit. Related biomarker reports may analyze the same parent cohort; do not count them as separate trials.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Effects of Quercetin and Citrulline on Nitric Oxide Metabolites and Antioxidant Biomarkers in Trained Cyclists
Jennifer A Kurtz et al. · Nutrients · 2025
Tier 2
Quercetin prophylaxis in prevention of acute mountain sickness (AMS): a randomized, double blind, placebo controlled phase-II clinical trials
Sarada S K Sagi et al. · European journal of nutrition · 2026
Tier 2
Quercetin ingestion alters motor unit behavior and enhances improvement in muscle strength following resistance training in older adults: a randomized, double-blind, controlled trial
Taichi Nishikawa et al. · European journal of nutrition · 2025

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology